(Q77354774)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9754946%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

review article

1 reference

title

Recent developments in HIV protease inhibitor therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9754946%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

author name string

A Molla

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9754946%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

G R Granneman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9754946%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

E Sun

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9754946%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

D J Kempf

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9754946%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

publication date

1 July 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9754946%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9754946%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9754946%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9754946%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

page(s)

1-23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9754946%20AND%20SRC:MED&resulttype=core&format=json

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

4 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

The HIV-1 protease as a therapeutic target for AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Resistance of HIV Type 1 to Proteinase Inhibitor Ro 31-8959

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

RNA virus populations as quasispecies.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Active human immunodeficiency virus protease is required for viral infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir).

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

Recovery of Replication-Competent HIV Despite Prolonged Suppression of Plasma Viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900011-4

7 January 2021

10.1016/S0166-3542(98)00011-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9754946%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

1 reference